NASDAQ: JAGX · Life Sciences · 12 alerts · CIK 1585608
Share price
$0.3864Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jaguar Health, Inc. filings on SEC EDGAR ↗
Jaguar Health reported its third quarter 2026 financial results, highlighting a significant $10.1 million reduction in outstanding debt. The company is transitioning to a distribution and R&D model following its U.S. commercial licensing agreement with Woodward Specialty, focusing on its rare disease intestinal failure program for crofelemer.
Jaguar Health reported a significant increase in total revenue to $23.8 million for the nine months ended September 30, 2026, primarily driven by $20.9 million in license revenue. Despite this, the company recorded a net loss of $9.9 million for the period, though this was a substantial improvement from the $30.8 million net loss in the prior year period.
Jaguar Health held a special meeting of stockholders on November 6, 2026, where all six submitted proposals were approved. Key approvals included the issuance of common stock upon exchange of Series Q Preferred Stock and debt, the repricing of investor warrants to $1.00 per share, an increase in authorized shares for the 2014 Stock Incentive Plan, and the authorization for a potential reverse stock split at a ratio between 1-for-2 and 1-for-150.
Jaguar Health announced the automatic conversion of its Series R Convertible Preferred Stock into common stock on November 2, 2026. Each share of Series R Preferred Stock, which was previously issued as a special dividend, converted into five shares of common stock, resulting in a total of 13,345,986 shares of common stock outstanding.
Jaguar Health filed a proxy supplement regarding Proposal 3 for its upcoming special meeting, seeking shareholder approval to increase the 2014 Stock Incentive Plan's authorized shares to 378,859. This share reserve represents 14% of the company's issued and outstanding common stock on a fully diluted basis as of September 30, 2026. The supplement clarifies the share count following a special one-time dividend of Series R Preferred Stock and its subsequent conversion into common stock.
Jaguar Health has declared a special stock dividend of Series R Convertible Preferred Stock to common stockholders and certain warrant holders of record as of October 13, 2026. Each share of the new preferred stock is scheduled to convert into five shares of common stock on November 2, 2026, a move intended to provide dilution protection to existing shareholders. Additionally, the company amended existing royalty interests and a promissory note to extend payment and maturity dates to January 1, 2027.
Jaguar Health $3.4M Debt Financing with Streeterville Capital, LLC
Jaguar Health entered into exchange agreements with Streeterville Capital to reduce the outstanding balance of a 2021 secured promissory note by $3.4 million. In exchange for this debt reduction, the company issued 481,584 shares of its common stock to the lender. The transaction was conducted as a privately negotiated exchange exempt from registration under Section 3(a)(9) of the Securities Act.
Jaguar Health $6.73M Debt Financing with Streeterville Capital, LLC
Jaguar Health entered into exchange agreements with Streeterville Capital to reduce its outstanding debt by approximately $6.73 million through the issuance of common stock. Specifically, the company issued 182,091 shares to reduce a 2021 note by $1.68 million and 547,898 shares to fully pay off and cancel a 2025 note valued at $5.05 million.
Jaguar Health $5.05M Debt Financing with Streeterville Capital, LLC
Jaguar Health entered into exchange agreements with Streeterville Capital to reduce the outstanding balance of a 2025 secured promissory note by approximately $5.05 million. In exchange for this debt reduction, the company issued 547,898 shares of common stock to the lender. This transaction effectively settles a portion of the company's existing debt obligations through equity issuance.
Jaguar Health, Inc. effected a 1-for-15 reverse stock split of its issued and outstanding common stock on September 17, 2026. Following the split, the company has approximately 520,088 shares of common stock outstanding. Additionally, the company filed a Certificate of Elimination to remove several series of preferred stock from its charter as no shares of those series remained outstanding.